Previous 10 | Next 10 |
Zogenix offers Data for Fintepla, Markets React Negatively Zogenix (ZGNX) stock tumbled as the company reported mixed data from its Phase 3 clinical trial of Fintepla. The trial involved evaluating two doses of the lead drug candidate in patients suffering from a severe form of childhood o...
Zogenix (NASDAQ: ZGNX) reported what it called "positive" results from a late-stage clinical trial testing its drug candidate, Fintepla, in patients with a variety of childhood-onset epilepsy called Lennox-Gastaut syndrome. And technically, the company was right: Fintepla reduced the median ...
Gainers: Benitec Biopharma (NASDAQ: BNTC ) +51% . More news on: Benitec Biopharma Limited, Assertio Therapeutics, Inc., Ocwen Financial Corporation, Stocks on the move, , Read more ...
Shares of Zogenix (NASDAQ: ZGNX) fell more than 32% today after the company reported positive top-line results from an important phase 3 study evaluating Fintepla as a treatment for a rare childhood form of epilepsy called Lennox-Gastaut syndrome (LGS). While the drug candidate achieved a st...
Arcturus Therapeutics (NASDAQ: ARCT ) initiated with Buy rating and $19 (70% upside) price target at Guggenheim. More news on: Arcturus Therapeutics Holdings Inc., BeyondSpring Inc., Millendo Therapeutics, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
Zogenix (NASDAQ: ZGNX ) slumps 33% after hours in reaction to its announcement of "successful" results from a Phase 3 clinical trial evaluating two doses of Fintepla (fenfluramine oral solution) (ZX008) in patients with a severe form of childhood-onset epilepsy called Lennox-...
Primary Endpoint Achieved - Statistically Significant Reduction in Drop Seizures for FINTEPLA 0.7 mg/kg/day versus Placebo FINTEPLA Also Demonstrated Statistically Significant Improvement on Multiple Secondary Endpoints Zogenix to Host Conference Call and Live Webcast...
This was expected to be the year that everything went right for the cannabis industry . To our north, Canada had become the first industrialized country in the world to legalize recreational marijuana and commenced sales in October 2018. Derivative products were also presumed to hit dispensary ...
Zogenix (NASDAQ: ZGNX ) announces that The Lancet has published the results of its Phase 3 trial for Fintepla in children and young adults with Dravet syndrome, a rare, catastrophic form of epilepsy. More news on: Zogenix, Inc., Healthcare stocks news, Read more ...
FINTEPLA as adjunctive therapy showed a significant, dose-dependent reduction in convulsive seizure frequency in Dravet syndrome patients versus placebo EMERYVILLE, Calif., Dec. 17, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare ...
News, Short Squeeze, Breakout and More Instantly...
UCB Completes Acquisition of Zogenix, Inc. - Broadens and builds upon UCB's role as a leader in, and our continued commitment to, addressing unmet needs of people living with epilepsy - Total transaction value of up to approximately US$ 1.9 billion / € 1.7 billion. Th...
Zogenix Inc. (NASDAQ:ZGNX) traded today at a new 52-week high of $26.66. Approximately 1.2 million shares have changed hands today, as compared to an average 30-day volume of 3.7 million shares. Zogenix Inc. (NASDAQ:ZGNX) defies analysts with a current price ($26.57) 0.4% above its avera...
Two podium and one poster presentation share important new findings on FINTEPLA’s safety profile and its impact on non-seizure related benefits for LGS patients LGS is a debilitating childhood-onset developmental and epileptic encephalopathy estimated to affect approx...